Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E.

Lancet. 2009 Aug 29;374(9691):682; author reply 683. doi: 10.1016/S0140-6736(09)61552-X. No abstract available.

PMID:
19716955
2.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

3.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

Cao YB, Zhang JD, Shen H, Jiang YY.

Eur J Clin Pharmacol. 2010 Nov;66(11):1099-108. doi: 10.1007/s00228-010-0889-z. Epub 2010 Sep 2.

PMID:
20812009
4.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators.

Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4.

PMID:
19411100
5.
7.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

8.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Longo UG, Maffulli N, Denaro V.

Lancet. 2009 Aug 29;374(9691):681-2; author reply 683. doi: 10.1016/S0140-6736(09)61551-8. No abstract available.

PMID:
19716953
9.

Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.

Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG.

Thromb Haemost. 2007 Jun;97(6):931-7.

PMID:
17549294
10.

Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Nieto JA, Espada NG, Merino RG, González TC.

Thromb Res. 2012 Aug;130(2):183-91. doi: 10.1016/j.thromres.2012.02.011. Epub 2012 Mar 15.

PMID:
22425218
11.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Raju NC, Dimmitt S, Eikelboom JW.

Lancet. 2009 Aug 29;374(9691):681; author reply 683. doi: 10.1016/S0140-6736(09)61549-X. No abstract available.

PMID:
19716954
12.

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.

Huisman MV, Quinlan DJ, Dahl OE, Schulman S.

Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):652-60. doi: 10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.

13.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Stief T.

Lancet. 2009 Aug 29;374(9691):681; author reply 683. doi: 10.1016/S0140-6736(09)61550-6. No abstract available.

PMID:
19716952
14.

The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.

Lassen MR, Gent M, Kakkar AK, Eriksson BI, Homering M, Berkowitz SD, Turpie AG.

J Bone Joint Surg Br. 2012 Nov;94(11):1573-8. doi: 10.1302/0301-620X.94B11.28955.

PMID:
23109641
15.

Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.

Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R.

Eur J Orthop Surg Traumatol. 2013 May;23(4):481-6. doi: 10.1007/s00590-012-0987-y. Epub 2012 Apr 17.

PMID:
23412293
16.

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M; OdiXa-Knee Study Group.

J Thromb Haemost. 2005 Nov;3(11):2479-86.

17.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
18.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

19.

Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S.

Thromb Haemost. 2013 Jan;109(1):154-63. doi: 10.1160/TH12-07-0510. Epub 2012 Nov 29.

PMID:
23197272
20.

A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.

Chahal GS, Saithna A, Brewster M, Gilbody J, Lever S, Khan WS, Foguet P.

Ortop Traumatol Rehabil. 2013 Mar-Apr;15(2):125-9. doi: 10.5604/15093492.1045953.

PMID:
23652532
Items per page

Supplemental Content

Write to the Help Desk